VRTX
Vertex Pharmaceuticals Inc.
$548.05
+1.44%
2026-08-21
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Key Fundamentals
P/E Ratio
29.51
Forward P/E
23.20
EPS (TTM)
$17.14
ROE
23.5%
Revenue Growth (YoY)
12.5%
Profit Margin
35.0%
Debt/Equity
9.77
Price/Book
6.33
Beta
0.30
Market Cap
$128.19B
Avg Volume (10D)
1.4M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$555.32
60D Low
$420.01
Avg Volume
1.5M
Latest Close
$548.05
Get breakout alerts for VRTX
Sign up for Breakout Scanner to receive daily notifications when VRTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Vertex Pharmaceuticals Inc. (VRTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors VRTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. VRTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.